Enzyme‐mediated synthesis of Molnupiravir: paving the way for the application of biocatalysis in pharmaceutical industry

  1. Cruz, Guillermo 1
  2. Acosta, Javier 1
  3. Del Arco, Jon 1
  4. Clemente‐Suarez, Vicente Javier 12
  5. Deroncele, Víctor 3
  6. Fernández‐Lucas, Jesús 12
  1. 1 Universidad Europea de Madrid
    info

    Universidad Europea de Madrid

    Madrid, España

    ROR https://ror.org/04dp46240

  2. 2 Universidad de la Costa
    info

    Universidad de la Costa

    Barranquilla, Colombia

    ROR https://ror.org/01v5nhr20

  3. 3 Selabtec Sciences C\ Àlvarez de Castro, 63 08100 Mollet del Vallès Spain
Mostrar afiliaciones +
Revista:
ChemCatChem

ISSN: 1867-3880,  1867-3899

Año de publicación: 2022

Tipo: Artículo

DOI: 10.1002/CCTC.202200140 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: ChemCatChem

Resumen

Molnupiravir (Lagevrio®) is an orally-administered anti-COVID-19 agent. Due to the urgency to meet the worldwide demand and the growing environmental concern, there is a need for speed in the industrial implementation of novel and efficient bioprocesses for Molnupiravir synthesis. This concept paper aims to review the most relevant milestones that have guided important developments in the enzyme-mediated synthesis of Molnupiravir, including detailed comments on the advantages and drawbacks of the different synthetic routes. Finally, based on a personal perspective, new greener processes for Molnupiravir manufacturing are proposed and discussed.

€ Ver financiación

Información de financiación

Financiadores

Referencias bibliográficas

  • 10.1038/nrd4010
  • 10.1021/cr900028p
  • 10.1002/asia.201900841
  • Cox R. M., (2021), Nat. Microbiol., 6, pp. 1, 10.1038/s41564-020-00847-y
  • 10.1002/9783527812103
  • 10.2174/138527208783743723
  • 10.1016/j.molcatb.2016.08.015
  • 10.1007/s00253-015-6642-x
  • Del Arco J., (2017), Curr. Pharm. Des., 23, pp. 6898
  • Kaspar F., (2020), Green Chem., 23, pp. 37, 10.1039/D0GC02665D
  • 10.1007/s00253-018-9242-8
  • 10.1038/s41564-020-00835-2
  • 10.1038/s41594-021-00651-0
  • 10.1016/j.jbc.2021.100867
  • Syed Y. Y., (2022), Drugs, 82, pp. 455, 10.1007/s40265-022-01684-5
  • Whitley R., (2022), N. Engl. J. Med., 386, pp. 592, 10.1056/NEJMe2117814
  • G. R. Painter G. R. Bluemling M. G. Natchus D. Guthrie WO2019113462 A1 2019;
  • G. R. Painter D. Perryman G. R. Bluemling WO2019173602 2019.
  • 10.1002/ejoc.202001340
  • Hu T., (2022), Org. Process Res. Dev., 2, pp. 358, 10.1021/acs.oprd.1c00419
  • 10.1039/D0CC05944G
  • 10.1055/a-1275-2848
  • 10.1021/acsomega.1c00772
  • 10.1021/acs.oprd.1c00033
  • 10.1021/acscentsci.1c00608
  • Jhulki I., (2021), ACS Cent. Sci., 7, pp. 1963, 10.1021/acscentsci.1c01356
  • Simić S., (2021), Chem. Rev., 122, pp. 1052, 10.1021/acs.chemrev.1c00574
  • 10.1186/1860-5397-2-3
  • 10.1021/jacs.1c11048
  • Mullin R., (2021), C&EN Global Enterprise, 99, pp. 19, 10.1021/cen-09906-buscon14
  • 10.1016/j.jbiosc.2017.01.005
  • 10.1016/j.jbiosc.2017.07.016
  • 10.2174/138527206777697995
  • Acosta J., (2020), Front. Bioeng. Biotechnol., 8, pp. 593, 10.3389/fbioe.2020.00593
  • 10.1002/cbic.201900397
  • 10.1128/AEM.07605-11
  • 10.1016/j.foodchem.2017.05.136
  • 10.1016/j.biortech.2020.124547
  • 10.1016/j.biortech.2021.125649
  • 10.3390/catal9040355
  • 10.1002/cpz1.347
  • 10.1016/j.jbiotec.2010.11.013
  • 10.1016/j.ijbiomac.2021.09.164
  • 10.1002/cbic.202000679
  • 10.1016/j.bbapap.2019.140304
  • 10.1016/j.biortech.2020.123258
  • Rivero C. W., (2021), Biomol. Eng., 11, pp. 657
  • 10.1002/adsc.200404019